EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study

Arvind Suresh, Heather A Wishart, Maeen N Arslan, Raphael A Lizcano, Parth S Shah, Swaroopa PonnamReddy, Christi Ann Hayes, Bryce S Jacobson, Grant Moncrief, Pablo Martinez-Camblor, Amy M Chan, Kenneth R Meehan und 1 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025-05 · 25 (5) · 365-378

DOI: 10.1016/j.clml.2024.12.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-05. Verfasst von Arvind Suresh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, CA. Electronic address: arvind.suresh@ucsf.edu. Hauptthemen laut MEDLINE: Neurotoxicity Syndromes, Immunotherapy, Adoptive, Neuropsychological Tests, Antigens, CD19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Society of Hematology, Dartmouth Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune effector cell-associated neurotoxicity syndrome (ICANS) can be a severe, life-threatening toxicity following CAR T-cell therapy. While currently evaluated by the immune effector cell-associated encephalopathy (ICE) score, not all patients have changes in their ICE score and not all signs and symptoms of neurotoxicity are captured. METHODS: We conducted a prospective, single center cohort pilot study to evaluate a novel, rapid neurocognitive assessment tool (CART-NS) in detecting early, subtle neurotoxicity prior to the onset of ICANS and any deterioration in the ICE score. CART-NS includes 8 abbreviated forms of neurocognitive tests and 2 symptom questionnaires. Following baseline measurements, CART-NS was administered at 8-hour intervals during the first 30 days after CAR T-cell infusion. RESULTS: Performance on all measures was significantly lower when patients developed Grade 1 or 2 ICANS (P < .05). Performance on Oral Symbol Digit, Stroop, and the Paced Visual Serial Addition Test was lower between Day 0 and +3 in patients who developed ICANS and persisted even after clinical resolution. Early changes in the Stroop test (AUC = 0.857, 95% CI 0.628-1.000) were most predictive of ICANS onset when measured during the first 36 hour following CAR T-cell infusion. Significant elevations in CRP, G-CSF, GM-CSF, IFNγ, IL-10, IL-15, IL-27, and MIG/CXCL-9 were associated with ICANS development. CONCLUSION: Brief neurocognitive testing can be feasibly applied for the early detection of ICANS after CAR T-cell therapy, predict which patients may go on to develop ICANS in the first 30 days, and overcome limitations of the ICE assessment tool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurotoxicity SyndromesImmunotherapy, AdoptiveNeuropsychological TestsAntigens, CD19Receptors, Chimeric AntigenHumansPilot ProjectsMaleFemaleMiddle AgedAgedAdultProspective Studies

Stichwörter der Autor:innen

BiomarkersEarly detectionICANS

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, CA. Electronic address: arvind.suresh@ucsf.edu.
  • Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Dartmouth College, Hanover, NH.
  • Transplant and Cellular Therapy Program, Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH.

Förderung

  • NCI NIH HHS
  • American Society of Hematology
  • Dartmouth Cancer Center

Zitieren

APA

Suresh, A., Wishart, H. A., Arslan, M. N., Lizcano, R. A., Shah, P. S., PonnamReddy, S., Hayes, C. A., Jacobson, B. S., Moncrief, G., Martinez-Camblor, P., Chan, A. M., Meehan, K. R., & Hill, J. M. (2025). Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study. Clinical Lymphoma Myeloma and Leukemia, 25(5), 365-378. https://doi.org/10.1016/j.clml.2024.12.011

Vancouver

Suresh A, Wishart HA, Arslan MN, Lizcano RA, Shah PS, PonnamReddy S, et al. Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study. Clinical Lymphoma Myeloma and Leukemia. 2025;25(5):365-378. doi:10.1016/j.clml.2024.12.011

BibTeX
@article{Suresh2025,
  author = {Suresh, Arvind and Wishart, Heather A and Arslan, Maeen N and Lizcano, Raphael A and Shah, Parth S and PonnamReddy, Swaroopa and Hayes, Christi Ann and Jacobson, Bryce S and Moncrief, Grant and Martinez-Camblor, Pablo and Chan, Amy M and Meehan, Kenneth R and Hill, John M},
  title = {Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  volume = {25},
  number = {5},
  pages = {365--378},
  doi = {10.1016/j.clml.2024.12.011}
}
Kostenlos starten →